Nebivolol Cinfa (Nebivolol Hydrochloride)

Nebivolol selectively blocks β1‑adrenergic receptors in the heart, decreasing heart rate and contractility. At the same time, it stimulates endothelial nitric‑oxide production, causing vasodilation. This combined effect reduces cardiac output and peripheral resistance, leading to a fall in arterial blood pressure.

The appropriate dose of Nebivolol Cinfa is determined by the prescribing clinician based on the patient’s clinical condition, age, renal and hepatic function, and response to therapy. The prescriber will select the strength and titration schedule that best meets the individual’s therapeutic needs.

Nebivolol is classified as a pregnancy category with limited data. It should be used only if the potential benefit justifies any potential risk to the fetus. Likewise, caution is advised during breastfeeding, as the drug may be excreted in breast milk. Consultation with a healthcare professional is essential.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifying trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Nebivolol offers a unique combination of β1‑selectivity and nitric‑oxide‑mediated vasodilation, which can provide better tolerability compared with non‑selective β‑blockers. Unlike ACE inhibitors or ARBs, it does not interfere with the renin‑angiotensin system, making it a suitable alternative for patients who cannot tolerate those agents.

Nebivolol Cinfa should be stored at ambient temperature, below 25 °C, in its original packaging to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Nebivolol Cinfa is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

Serious adverse events, though uncommon, include marked bradycardia, severe hypotension, heart block, and acute bronchospasm. Patients should be monitored for symptoms such as faintness, slow heart rate, or difficulty breathing, and medical attention should be sought promptly if these occur.

Nebivolol is contraindicated in patients with known hypersensitivity to nebivolol or any excipients, those with severe bradycardia, second‑ or third‑degree heart block without a pacemaker, and individuals experiencing cardiogenic shock. It should also be used with caution in patients with severe hepatic impairment.